Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$106.44 USD

106.44
1,208,547

-1.65 (-1.53%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates

Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Abiomed Gets CDSCO Nod for Impella Heart Pumps in India

    Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.

      Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

      Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.

        Stryker (SYK) Beats on Q2 Earnings, International Sales Up

        Stryker (SYK) gains from solid segmental performance in Q2.

          Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates

          Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.

            Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance

            Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.

              OPKO Health's RAYALDEE Gets Approval in Canada to Treat CKD

              OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.

                Intuitive Surgical's FDA Approval for SureForm to Aid Surgery

                Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.

                  MASI or STE: Which Is a Better Investment Option Right Now?

                  Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.

                    Here's Why You Should Invest in Masimo (MASI) Right Now

                    Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.

                      Integer Holdings Offloads AS&O, Focuses on Cardiac Units

                      Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.

                        MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE

                        Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.

                          Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring

                          Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.

                            Why Is Masimo (MASI) Up 9.2% Since Its Last Earnings Report?

                            Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance

                              Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.

                                Medical Product Stock Earnings on May 2: CERN, ABC & More

                                Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.

                                  Masimo Gets CE Mark for NomoLine, Expands in Capnography

                                  Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.

                                    Why Masimo (MASI) Could Beat Earnings Estimates Again

                                    Masimo (MASI) can be a harbinger of outperformance and a signal for a strong earnings profile on the back of solid Zacks rank and positive earnings ESP.

                                      Masimo (MASI) Launches UniView, Improves Patient Safety

                                      Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.

                                        Here's Why You Should Invest in Masimo (MASI) Right Now

                                        Masimo (MASI) rides on solid earnings results and a wide array of products.

                                          Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive

                                          Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.

                                            Masimo Products to Boost India-Based NU Hospitals' Systems

                                            Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.

                                              Masimo's SpHb Hemoglobin Monitoring Study Results Positive

                                              New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.

                                                Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis

                                                Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.

                                                  Masimo (MASI) Receives FDA Approval for SedLine, Shares Up

                                                  Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.